Home >> Life Sciences >> Pharmaceuticals >> Prescription Drugs >> Gastrointestinal

Gastroenteritis - Pipeline Review, H2 2015

Published: Nov-2015 | Format: PDF | Global Markets Direct | Number of pages: 55 | Code: MRS - 41783

Gastroenteritis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Gastroenteritis - Pipeline Review, H2 2015’, provides an overview of the Gastroenteritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroenteritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroenteritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastroenteritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastroenteritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastroenteritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroenteritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroenteritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastroenteritis Overview 6
Therapeutics Development 7
Pipeline Products for Gastroenteritis - Overview 7
Pipeline Products for Gastroenteritis - Comparative Analysis 8
Gastroenteritis - Therapeutics under Development by Companies 9
Gastroenteritis - Therapeutics under Investigation by Universities/Institutes 10
Gastroenteritis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Gastroenteritis - Products under Development by Companies 14
Gastroenteritis - Products under Investigation by Universities/Institutes 15
Gastroenteritis - Companies Involved in Therapeutics Development 16
Cocrystal Pharma, Inc. 16
Nanotherapeutics, Inc. 17
RedHill Biopharma Ltd. 18
Takeda Pharmaceutical Company Limited 19
UMN Pharma Inc. 20
Gastroenteritis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Antibodies for Gastroenteritis - Drug Profile Product Description 30
Mechanism of Action 30
R&D Progress 30
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
norovirus (bivalent) virus like particle vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ondansetron hydrochloride CR - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Acute Gastroenteritis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TAK-214 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
UMN-2002 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
UMN-2003 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Gastroenteritis - Recent Pipeline Updates 40
Gastroenteritis - Product Development Milestones 46
Featured News & Press Releases 46
Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D 46
Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 47
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 48
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 49
Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 50
Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 51
Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development for Gastroenteritis, H2 2015 7
Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Gastroenteritis - Pipeline by Cocrystal Pharma, Inc., H2 2015 16
Gastroenteritis - Pipeline by Nanotherapeutics, Inc., H2 2015 17
Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H2 2015 18
Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 19
Gastroenteritis - Pipeline by UMN Pharma Inc., H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Gastroenteritis Therapeutics - Recent Pipeline Updates, H2 2015 40

List of Figures
Number of Products under Development for Gastroenteritis, H2 2015 7
Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Targets, H2 2015 22
Number of Products by Stage and Targets, H2 2015 22
Number of Products by Mechanism of Actions, H2 2015 24
Number of Products by Stage and Mechanism of Actions, H2 2015 24
Number of Products by Routes of Administration, H2 2015 26
Number of Products by Stage and Routes of Administration, H2 2015 26
Number of Products by Molecule Types, H2 2015 28
Number of Products by Stage and Molecule Types, H2 2015 28

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Related Reports

EMEA (Europe, Middle East and Africa) Vegetable Capsules Market 2017 Forecast to 2022

Jan-2018 | Global Info Research | Pages : 124 | Code : MRS-214954 | 4480

Pill is a common part of many people’s lives for pharmaceutical use or as health Supplements, It has two main forms of tablets and capsules. Tablets were the most popular way to take medicine for quite some time. While since some characters such as hard to swallow and slice, too many additives and so on, most people tend to switch to capsules from the industrialization era on when capsule shells technologies and filling machines have been developed. Scope of the Report: This report fo Read more

EMEA (Europe, Middle East and Africa) Sugar Sphere Market Professional Survey Market 2017 Forecast to 2022

Jan-2018 | Global Info Research | Pages : 121 | Code : MRS-214864 | 4480

Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere Market Professional Survey in EMEA market, covering Europe, Middle East and Africa, This report c Read more

Global Active Pharmaceutical Ingredients Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Feb-2018 | Global Info Research | Pages : 103 | Code : MRS-214050 | 3480

This report studies the Active Pharmaceutical Ingredients market. An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical sub Read more

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Gene Synthesis Market 2018 Forecast to 2023

Feb-2018 | Global Info Research | Pages : 105 | Code : MRS-214049 | 4880

Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. Sco Read more

Global Botox Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Feb-2018 | Global Info Research | Pages : 108 | Code : MRS-214048 | 3480

Botox is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species in the reproduction process. Botox is a polypeptide which molecular weight is 150kD and is also one of the most poisonous natural proteins. It is so easy to be produced, purified and refined due to its stable property that Botox is used widely in Experimental Research and Clinical Application at the early stage. Scope of the Report: This report focuses on the Botox in global market, especia Read more

Global Pharmaceutical Hot Melt Extruder Market Research Report by Product Type, Application, Regions and Outlook 2017-2023

Jan-2018 | HeyReport | Pages : 77 | Code : MRS-213925 | 2030

Summary The global Pharmaceutical Hot Melt Extruder market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows: Read more

2018-2023 United States Neurofeedback System Market Report (Status and Outlook)

Feb-2018 | LPI (LP Information) | Pages : 89 | Code : MRS-213213 | 3360

In 2017, the Neurofeedback System market size was xx million in United States, and it will be xx million in 2023, with a CAGR of xx% between 2017 and 2023. In United States market, the top players include BrainMaster Technologies BEE Medic Brainquiry Mitsar Thought Technology Mind Media Wearable Sensing Split by product types/category, covering Slow Cortical Potential Neurofeedback (SCP-NF) Low-energy Neurofeedback System (LENS) Hemo Read more

2018-2023 UK Neurofeedback System Market Report (Status and Outlook)

Feb-2018 | LPI (LP Information) | Pages : 89 | Code : MRS-213212 | 3360

In 2017, the Neurofeedback System market size was xx million in UK, and it will be xx million in 2023, with a CAGR of xx% between 2017 and 2023. In UK market, the top players include BrainMaster Technologies BEE Medic Brainquiry Mitsar Thought Technology Mind Media Wearable Sensing Split by product types/category, covering Slow Cortical Potential Neurofeedback (SCP-NF) Low-energy Neurofeedback System (LENS) Hemoencephalographic (HEG) Read more

2018-2023 Philippines Neurofeedback System Market Report (Status and Outlook)

Feb-2018 | LPI (LP Information) | Pages : 89 | Code : MRS-213211 | 3360

In 2017, the Neurofeedback System market size was xx million in Philippines, and it will be xx million in 2023, with a CAGR of xx% between 2017 and 2023. In Philippines market, the top players include BrainMaster Technologies BEE Medic Brainquiry Mitsar Thought Technology Mind Media Wearable Sensing Split by product types/category, covering Slow Cortical Potential Neurofeedback (SCP-NF) Low-energy Neurofeedback System (LENS) Hemoence Read more

2018-2023 Malaysia Neurofeedback System Market Report (Status and Outlook)

Feb-2018 | LPI (LP Information) | Pages : 89 | Code : MRS-213210 | 3360

In 2017, the Neurofeedback System market size was xx million in Malaysia, and it will be xx million in 2023, with a CAGR of xx% between 2017 and 2023. In Malaysia market, the top players include BrainMaster Technologies BEE Medic Brainquiry Mitsar Thought Technology Mind Media Wearable Sensing Split by product types/category, covering Slow Cortical Potential Neurofeedback (SCP-NF) Low-energy Neurofeedback System (LENS) Hemoencephalog Read more

  • Payment Mode
Single User | $(USD)2000 View Pricing